Welcome to BioMarin's Online Press Room.
We've brought together a variety of information in one location
to better assist you in your efforts to research and develop
news articles. Should you require additional information, please
call or e-mail us any time.
BioMarin Announces FDA Accepts Drisapersen NDA for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping... MORE >BioMarin Announces EMA Validates MAA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping... MORE >BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study... MORE >